Sorted By:

Relevance


Economic Impact

PhRMA  |  From PhRMA

Explore the interactive map below and select a state to access data on biopharmaceutical jobs, the industry's overall economic impact, clinical trial activity, and more. 
https://www.phrma.org/resources/state-map

PPA: 2016 in review

PhRMA  |  Blog Post

PPA Video “Information for Patient Advocates” PPA Brochure
http://catalyst.phrma.org/ppa-2016-in-review

Copay coupons can help ease patients' out-of-pocket costs

PhRMA  |  Blog Post

For example, PBMs can exclude the brand medicine from the formulary or subject it to prior authorization or step therapy.
http://catalyst.phrma.orghttps://catalyst.phrma.org/copay-coupons-can-help-ease-patients-out-of-pocket-costs

Clinical Trials

PhRMA  |  From PhRMA

Explore the interactive map below and select a state to access data on biopharmaceutical jobs, the industry's overall economic impact, clinical trial activity, and more. 
https://www.phrma.org/resources/state-map/clinical-trials

Medicare Monday: What is IPAB, and why is it bad for patients?

PhRMA  |  Blog Post

The full letter can be found here. 
http://catalyst.phrma.org/medicare-monday-what-is-ipab-and-why-is-it-bad-for-patients

Medicare Monday: How Part B has evolved over the years

PhRMA  |  Blog Post

Learn more about Part B at PhRMA.org/PartB.
http://catalyst.phrma.org/how-part-b-has-evolved-over-the-years

Share the Savings - Your insurer doesn't pay full price for medicines. So why do you?

PhRMA  |  Graphic

Your insurer doesn't pay full price for medicines.
https://www.phrma.org/graphic/share-the-savings-your-insurer-doesn-t-pay-full-price-for-medicines-so-why-do-you

Medicare Monday: Did you know Medicare Part B uses a market-based system to pay for medicines?

PhRMA  |  Blog Post

ASP+6% gives these providers added support to remain competitive with larger purchasers that can often acquire medicines at a lower price.
http://catalyst.phrma.org/medicare-monday-did-you-know-medicare-part-b-uses-a-market-based-system-to-pay-for-medicines

Compulsory licensing: A misused and abused international trade law

PhRMA  |  Blog Post

For decades, international trade law has protected innovative ideas so they can thrive and propagate.
http://catalyst.phrma.org/compulsory-licensing-a-misused-and-abused-international-trade-law

Commercially-Insured Patients Pay Undiscounted List Prices for One In Five Brand Prescriptions, Accounting for Half of Out-of-Pocket Spending on Brand Medicines

PhRMA  |  Report

Patients with deductibles and coinsurance for prescription medicines pay cost-sharing that is based on the undiscounted list price of a medicine, rather than the discounted price negotiated by their health plan or pharmacy benefit manager (PBM).
https://www.phrma.org/report/commercially-insured-patients-pay-undiscounted-list-prices-for-one-in-five-brand-prescriptions-accounting-for-half-of-out-of-pocket-spending-brand-medicines

Medicare Monday: 3 reasons why repealing Part D’s noninterference clause is a bad idea

PhRMA  |  Blog Post

Such proposals overlook the way the program currently works and how substantial negotiation is helping keep costs low for beneficiaries.
http://catalyst.phrma.org/medicare-monday-3-reasons-why-repealing-part-ds-noninterference-clause-is-a-bad-idea

PhRMA Announces Support for Seven-Day Script Limit on Opioid Medicines for Acute Pain

PhRMA  |  Press Release

PhRMA has been working closely with the Commission, the National Institutes of Health (NIH), and the Food and Drug Administration to develop a public-private partnership that will accelerate the development of non-opioid, non-addictive pain medicines and medication assisted treatments for long-term addiction recovery.
https://www.phrma.org/press-release/phrma-announces-support-for-seven-day-script-limit-on-opioid-medicines-for-acute-pain

PhRMA Statement on Part D Provision in Budget Deal

PhRMA  |  Press Release

The competitive market in Part D has kept program costs low for more than a decade.
https://www.phrma.org/press-release/phrma-statement-on-part-d-provision-in-budget-deal

Fact Check Friday: The truth about IPAB

PhRMA  |  Blog Post

That Joint Resolution has already been introduced in the House and the Senate – all that is left is for Congress to pass the Joint Resolution so that it can be enacted by the August 15, 2017, deadline.
http://catalyst.phrma.org/fact-check-friday-the-truth-about-ipab

Trading fair means upholding the law: A focus on patents

PhRMA  |  Blog Post

But this system has never been more at risk around the world.
http://catalyst.phrma.org/trading-fair-means-upholding-the-law-a-focus-on-patents

World AIDS Day 2017: Scientific breakthroughs paving the way for an AIDS-free generation

PhRMA  |  Blog Post

Advances in HIV/AIDS research and development are benefitting patients like Eric who was diagnosed with HIV at the age of just 25.
http://catalyst.phrma.org/world-aids-day-2017-scientific-breakthroughs-paving-the-way-for-an-aids-free-generation

Medicare Monday: Why imposing Medicaid-style rebates in Part D is a bad idea

PhRMA  |  Blog Post

Since its creation, Part D has provided beneficiaries with affordable access to comprehensive prescription drug coverage.
http://catalyst.phrma.org/medicare-monday-why-imposing-medicaid-style-rebates-in-part-d-is-a-bad-idea

Scientist Profile: Tom Marsilje, PhD

PhRMA  |  Video

Watch to hear his story or read more here.
https://www.phrma.org/video/scientist-profile-tom-marsilje-phd

Chart Pack: Cancer Medicines Value in Context

PhRMA  |  Report

This chart pack provides facts and figures about the role innovative treatments play in the fight against cancer.   
https://www.phrma.org/report/chart-pack-cancer-medicines-value-in-context

Print Ad: What is your insurer making you pay?

PhRMA  |  Graphic

What’s skyrocketing – the cost of your medicine...or what your insurer is making you pay for it?
https://www.phrma.org

Rare Disease Day: Accelerating innovation for patients in need

PhRMA  |  Blog Post

Advancing the use of patient-focused drug development tools, novel clinical trial designs, and emerging, qualified biomarkers can help reduce uncertainty in the drug development process and ensure that researchers are incorporating the patient perspective into each aspect of the development and review of new medicines.
http://catalyst.phrma.org/rare-disease-day-accelerating-innovation-for-patients-in-need

Exchanges State Map

PhRMA  |  From PhRMA

Take a look at the state map below to view key facts about 2016 health plans and prescription drug coverage in your state's health insurance exchange. 
https://www.phrma.org/media/exchanges-state-map

PPA connects nearly 10 million people; Celebrates 11th anniversary and launches mobile app

PhRMA  |  Blog Post

To date, PPA has connected more than 1 million people with free health care clinics throughout the United States.
http://catalyst.phrma.org/ppa-celebrates-11th-anniversary-and-launches-mobile-app

IPAB Pocket Card

PhRMA  |  Graphic

...
https://www.phrma.org/graphic/ipab-pocket-card

Medicare Monday: Call for repeal of IPAB intensifies

PhRMA  |  Blog Post

Learn more about IPAB and why it’s bad for patients here.
http://catalyst.phrma.org/medicare-monday-call-for-repeal-of-ipab-intensifies

You have reviewed the first 25 results out of 2219. Each page contains 25 results. You're on page 1.

prev 1 2 3 4 5 6 next